BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang R, Xu Y, Dai Z, Lin X, Wang H. The Immunologic Role of Gut Microbiota in Patients with Chronic HBV Infection. J Immunol Res 2018;2018:2361963. [PMID: 30148173 DOI: 10.1155/2018/2361963] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Xiao W, Lu MH, Rong PF, Zhang HY, Gong J, Peng YQ, Gong HY, Liu ZG. 11β‑hydroxysteroid dehydrogenase‑1 is associated with the activation of hepatic stellate cells in the development of hepatic fibrosis. Mol Med Rep 2020;22:3191-200. [PMID: 32945429 DOI: 10.3892/mmr.2020.11423] [Reference Citation Analysis]
2 Yang X, Lu D, Zhuo J, Lin Z, Yang M, Xu X. The Gut-liver Axis in Immune Remodeling: New insight into Liver Diseases. Int J Biol Sci 2020;16:2357-66. [PMID: 32760203 DOI: 10.7150/ijbs.46405] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
3 Zhao L, Yang Q, Liu J. Clinical Value Evaluation of microRNA-324-3p and Other Available Biomarkers in Patients With HBV Infection-Related Hepatocellular Carcinoma. Open Forum Infect Dis 2021;8:ofab108. [PMID: 34189151 DOI: 10.1093/ofid/ofab108] [Reference Citation Analysis]
4 Sadiq FA. Is it time for microbiome-based therapies in viral infections? Virus Res 2021;291:198203. [PMID: 33132161 DOI: 10.1016/j.virusres.2020.198203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Lu YX, Chang YZ, Liang P, Yang CQ. Effect of Additional Clostridium butyricum on the Intestinal Flora of Chronic Hepatitis B Patients Treated with Entecavir. Infect Dis Ther 2021;10:1519-30. [PMID: 34132991 DOI: 10.1007/s40121-021-00463-1] [Reference Citation Analysis]
6 Labarta-Bajo L, Gramalla-Schmitz A, Gerner RR, Kazane KR, Humphrey G, Schwartz T, Sanders K, Swafford A, Knight R, Raffatellu M, Zúñiga EI. CD8 T cells drive anorexia, dysbiosis, and blooms of a commensal with immunosuppressive potential after viral infection. Proc Natl Acad Sci U S A 2020;117:24998-5007. [PMID: 32958643 DOI: 10.1073/pnas.2003656117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zheng R, Wang G, Pang Z, Ran N, Gu Y, Guan X, Yuan Y, Zuo X, Pan H, Zheng J, Wang F. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma. Cancer Med 2020;9:4232-50. [PMID: 32281295 DOI: 10.1002/cam4.3045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
8 Montella L, Sarno F, Ambrosino A, Facchini S, D'Antò M, Laterza MM, Fasano M, Quarata E, Ranucci RAN, Altucci L, Berretta M, Facchini G. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma. Cells 2021;10:1909. [PMID: 34440678 DOI: 10.3390/cells10081909] [Reference Citation Analysis]
9 Zaongo SD, Ouyang J, Chen Y, Jiao Y, Wu H, Chen Y. HIV Infection Predisposes to Increased Chances of HBV Infection: Current Understanding of the Mechanisms Favoring HBV Infection at Each Clinical Stage of HIV Infection. Front Immunol 2022;13:853346. [DOI: 10.3389/fimmu.2022.853346] [Reference Citation Analysis]
10 Lan W, Wang Y, Zhou Z, Sun X, Zhang Y, Zhang F. Metabolic Regulation of Hepatitis B Virus Infection in HBV-Transgenic Mice. Metabolites 2022;12:287. [DOI: 10.3390/metabo12040287] [Reference Citation Analysis]
11 Lechner S, Yee M, Limketkai BN, Pham EA. Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction. Dig Dis Sci 2020;65:897-905. [PMID: 32020359 DOI: 10.1007/s10620-020-06100-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
12 Kassa Y, Million Y, Gedefie A, Moges F. Alteration of Gut Microbiota and Its Impact on Immune Response in Patients with Chronic HBV Infection: A Review. Infect Drug Resist 2021;14:2571-8. [PMID: 34262302 DOI: 10.2147/IDR.S305901] [Reference Citation Analysis]
13 Zhang ZQ, Shi BS, Lu W, Liu DP, Huang D, Feng YL. Quantitative HBcrAg and HBcAb versus HBsAg and HBV DNA in predicting liver fibrosis levels of chronic hepatitis B patients. Gastroenterol Hepatol 2020;43:526-36. [PMID: 32921478 DOI: 10.1016/j.gastrohep.2020.03.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Qian S, Golubnitschaja O, Zhan X. Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles. EPMA J 2019;10:365-81. [PMID: 31832112 DOI: 10.1007/s13167-019-00194-x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 19.0] [Reference Citation Analysis]
15 Ouyang J, Zaongo SD, Zhang X, Qi M, Hu A, Wu H, Chen Y. Microbiota-Meditated Immunity Abnormalities Facilitate Hepatitis B Virus Co-Infection in People Living With HIV: A Review. Front Immunol 2021;12:755890. [PMID: 35069530 DOI: 10.3389/fimmu.2021.755890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Juno JA, Eriksson EM. γδ T-cell responses during HIV infection and antiretroviral therapy. Clin Transl Immunology 2019;8:e01069. [PMID: 31321033 DOI: 10.1002/cti2.1069] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
17 Shao Y, Jiang Y, Li H, Zhang F, Hu Z, Zheng S. Characteristics of mouse intestinal microbiota during acute liver injury and repair following 50% partial hepatectomy. Exp Ther Med 2021;22:953. [PMID: 34335895 DOI: 10.3892/etm.2021.10385] [Reference Citation Analysis]
18 Milosevic I, Vujovic A, Barac A, Djelic M, Korac M, Radovanovic Spurnic A, Gmizic I, Stevanovic O, Djordjevic V, Lekic N, Russo E, Amedei A. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. Int J Mol Sci. 2019;20:395. [PMID: 30658519 DOI: 10.3390/ijms20020395] [Cited by in Crossref: 82] [Cited by in F6Publishing: 79] [Article Influence: 27.3] [Reference Citation Analysis]
19 Lu YX, He CZ, Wang YX, Ai ZS, Liang P, Yang CQ. Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study. Infect Dis Ther 2021;10:241-52. [PMID: 33111216 DOI: 10.1007/s40121-020-00355-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Li X, Wu S, Du Y, Yang L, Li Y, Hong B. Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model. Int J Antimicrob Agents 2020;56:106000. [PMID: 32360229 DOI: 10.1016/j.ijantimicag.2020.106000] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
21 Gu S, Fu X, Ye G, Chen C, Li X, Zhong S, Tang L, Chen H, Jiang D, Hou J, Li Y. High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection. Front Immunol 2021;12:649197. [PMID: 34234772 DOI: 10.3389/fimmu.2021.649197] [Reference Citation Analysis]